Circulating miRNA-20a and miRNA-203 for screening lymph node metastasis in early stage cervical cancer

Genetic Testing and Molecular Biomarkers

Volumn 17, Issue 8, 2013, Pages 631-636

  Zhao, Shan ^a   Yao, Desheng ^a   Chen, Junying ^a   Ding, Nan ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 203; MICRORNA 20A; UNCLASSIFIED DRUG; MIRN203 MICRORNA, HUMAN; RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER SCREENING; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; BLOOD; CANCER STAGING; CLINICAL TRIAL; GENE EXPRESSION REGULATION; MIDDLE AGED; UTERINE CERVIX TUMOR;

ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84881119197     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2013.0085     Document Type: Article

References (28)

1. Akobeng AK (2007) Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr 96:644-647.
2. Baffa R, Fassan M, Volinia S, et al. (2009) MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 219:214-221.
3. Cheung TH, Man KN, Yu MY, et al. (2012) Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm. Cell Cycle 11:2876-2884.
4. Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6:259-269.
5. Fischer JE, Bachman LM, Jaeschke R (2003) A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med 29:1043-1051.
6. Fassina A, Marino F, Siri M, et al. (2012) The miR-17-92 micro- RNA cluster: a novel diagnostic tool in large B-cell malignancies. Lab Invest 92:1574-1582.
7. Gu J, Wang Y, Wu X (2013) MicroRNA in the pathogenesis and prognosis of esophageal cancer. Curr Pharm Des 19:1292-1300.
8. Huang G, Nishimoto K, Zhou Z, et al. (2012) miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res 72:908-916.
9. Heneghan HM, Nicola Miller N, Kerin M (2010) Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol 28:e573-e574.
10. Ikenaga N, Ohuchida K, Mizumoto M, et al. (2010) MicroRNA- 203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol 17:3120-3128.
11. Kim BH, Hong SW, Kim A, et al. (2012) Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol 107:505-510.
12. Kang HW, Wang F, Wei Q, et al. (2012) miR-20a promotes migration and invasion by regulatingTNKS2 in human cervical cancer cells. FEBS Lett 586:897-904.
13. Kawaguchi T, Komatsu S, Ichikawa D, et al. (2013) Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer 108:361-369.
14. Lawrie CH, Gal S, Dunlop HM, et al. (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141: 672-675.
15. Lu Y, Thomson JM, Wong HY, et al. (2007) Transgenic overexpression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev Biol 310:442-453.
16. Madhavan D, Zucknick M, Wallwiener M, et al. (2012) Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res 18:5972-5982.
17. Ota A, Tagawa H, Karnan S, et al. (2004) Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 64:3087-3095.
18. Sakuragi N (2007) Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer. Int J Clin Oncol 12:165-175.
19. Takeshita N, Mori M, Kano M, et al. (2012) miR-203 inhibits the migration and invasion of esophageal squamous cell carcinoma by regulating LASP1. Int J Oncol 41:1653-1661.
20. Taylor DD, Gercel-Taylor C (2008) MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110:13-21.
21. Turchinovich A, Weiz L, Langheinz A, et al. (2012) Characterization of extracellular circulating microRNA. Nucleic Acids Res 39:7223-7233.
22. Valadi H, Ekstrom K, Bossios A, et al. (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654-659.
23. Ventura A, Young AG, Winslow MM, et al. (2008) Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132:875-886.
24. Viticchie G, Lena AM, Latina A, et al. (2011) MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle 10:1121-1131.
25. Wang W, Corrigan-Cummins M, Hudson J, et al. (2012) Micro- RNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica 97:586-594.
26. Waters PS, McDermott AM, Wall D, et al. (2012) Relationship between circulating and tissue microRNAs in a murine model of breast cancer. PLoS One 7:e50459.
27. Xiao C, Srinivasan L, Calado DP, et al. (2008) Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9:405-414.
28. Zeng X, Xiang J, Wu M, et al. (2012) Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One 7:e46367.